generation run 2026-05-09
119 min completedmodel pipeline-v5plan not recordedrun/61804588…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- taper_protocol_class_level
- taper_case_report_single
- icu_taper_gap
Reproduce
- inputs
- 46 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
27 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | ClinicalTrials.gov | midazolam sedation anesthesia | 10 | 2 | Relevant to midazolam clinical applications |
| 2 | PubChem | midazolam | 1 | 1 | Primary chemical identity verification |
| 3 | OpenAlex | midazolam benzodiazepine pharmacology | 10 | 2 | — |
| 4 | PubMed | PMID 3319363 | 1 | — | Key historical and clinical source |
| 5 | PubMed | midazolam sedation amnesia clinical review anesthesia premedication | 3 | 3 | Foundational clinical pharmacology sources |
| 6 | PubMed | midazolam pharmacokinetics oral intravenous bioavailability half-life human | 10 | 3 | Direct midazolam PK data |
| 7 | PubMed · absence | midazolam history synthesis discovery imidazobenzodiazepine | 0 | — | Will use web search as fallback for history |
| 8 | PubMed | midazolam pharmacology GABA receptor mechanism of action | 11 | 4 | Directly relevant to midazolam mechanism of action and pharmacogenomics |
| 9 | PubMed | PMID 3156545 | 1 | — | Key historical source |
| 10 | PubMed | midazolam status epilepticus intramuscular intranasal buccal | 10 | 6 | Key clinical use evidence for midazolam in seizure emergencies |
| 11 | WebSearch | midazolam history synthesis 1976 Squibb Fryer Walser discovery first benzodiazepine imidazole ring | 10 | 2 | History not available via API; web fallback confirmed key dates |
| 12 | PubMed | midazolam 1-hydroxymidazolam active metabolite glucuronide accumulation | 3 | 2 | Key safety findings about active metabolites |
| 13 | PubMed | midazolam intranasal spray Nayzilam seizure cluster FDA approval | 7 | 2 | Nayzilam approval and clinical profile |
| 14 | PubMed | midazolam palliative care continuous sedation terminal sedation end of life | 8 | 2 | Palliative care clinical use context |
| 15 | PubMed | PMID 3395535 | 1 | — | PK in hepatic disease |
| 16 | PubMed | midazolam flumazenil reversal benzodiazepine antagonist overdose | 8 | 3 | Reversal pharmacology and overdose management |
| 17 | PubMed | PMID 6742481 | 1 | — | Foundational PK data |
| 18 | PubMed | PMID 18175099 | 1 | — | Key comprehensive pharmacology source |
| 19 | WebSearch | midazolam FDA approval history 1985 Versed WHO essential medicines list execution lethal injection | 10 | 3 | Regulatory history and controversial use context |
| 20 | WebSearch | midazolam DEA Schedule IV controlled substance legal status UK EU scheduling | 10 | 2 | Legal status data not available via API |
| 21 | WebSearch | midazolam Australia Schedule 8 Canada controlled substance | 10 | — | International legal status |
| 22 | Multiple | Cross-referencing seed data vs. published sources | — | — | Data integrity check |
| 23 | WebSearch | midazolam physical properties melting point solubility stereochemistry racemic chiral active enantiomer | 10 | — | Stereochemistry and physical property data |
| 24 | WebSearch | midazolam FDA approval history 1985 Versed WHO essential medicines lethal injection | 10 | — | Regulatory and historical context |
| 25 | PubMed | PMID 6138079 safety aspects midazolam | 1 | — | Primary toxicology/safety data source |
| 26 | PubMed | benzodiazepine tolerance mechanism GABA receptor downregulation subunit changes | 3 | 2 | Molecular basis of tolerance development |
| 27 | OpenAlex | midazolam sedation dose pharmacodynamics amnesia anterograde | 8 | 4 | Most-cited papers on midazolam pharmacology and sedation |
97 claims by section — every cited sentence, checked against its source
safety28 · 20 ok
Animal LD50 data establish a wide therapeutic margin for midazolam alone: oral LD50 is approximately 1,600 mg/kg in both rats and mice; IV LD50 is 75 mg/kg (rat) and 50 mg/kg (mouse)supported
LD50 oral rat/mouse ~1600 mg/kg; IV LD50 75 mg/kg rat, 50 mg/kg mouse. pmid:6138079
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
The risk of clinically significant respiratory depression increases markedly when combined with opioids (synergistic effect) and in elderly patientssupported
Synergistic interactions with opioids. 978-3-540-74806-9_16
Midazolam is self-administered by non-human primates, confirming reinforcing properties and abuse liabilitysupported
TPA023B blocked midazolam self-administration in rhesus monkeys. s41398-025-03762-0
Claim in safety — inconclusiveinconclusiveworking →
The effect is reversible with flumazenil.supported
Five patients with severe renal failure had prolonged sedation reversed by flumazenil. pmid:7603229
Animal studies show no embryotoxicity, teratogenicity, or mutagenicity (Ames test and fluctuation test negative)supported
Not embryotoxic, not teratogenic. No effect on fertility or postnatal development. No mutagenic effect in Ames test. pmid:6138079
Anterograde amnesia is the most prominent cognitive effect, occurring reliably at sub-sedating doses and intensifying with dose and agesupported
Midazolam dose in preoperative holding area and patient age both associated with amnesia of OR before induction. pmid:26859877
In neonates, myoclonic-like movements have been reported and respond to flumazenil reversal.supported
Three term newborns developed myoclonic-like abnormal movements after midazolam. In one, flumazenil controlled them. pmid:11349753
Claim in safety — inconclusiveinconclusiveworking →
Two molecular mechanisms are established: transcriptional downregulation of the GABA-A receptor α1 subunit gene via activation of L-type voltage-gated calcium channels, and receptor uncoupling through increased phosphorylation of the γ2 subunitpartially supported
Chronic benzodiazepine exposure produces tolerance via uncoupling of GABA and BZD sites and transcriptional downregulation of GABA-A receptor alpha1 subunit through L-type voltage-gated calcium channel activation. j.neulet.2020.134801
Claim in safety — inconclusiveinconclusiveworking →
In pediatric cardiac ICU patients, dose-dependent tolerance requiring escalating infusion rates has been documented during continuous midazolam administration.supported
Midazolam has dose-dependent potential to induce tolerance, withdrawal, and hemodynamic depression in pediatric ICU. 0218492315585644
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
She was treated with gradual transition to equivalent oral clonazepam dosing over seven days, supplemented with carbamazepine and cognitive behavioral therapy.supported
Transitioned to clonazepam taper plus carbamazepine and CBT. yic.0000000000000486
Residual interaction at four hours post-IV midazolam-fentanyl sedation is not clinically significant, but concurrent use at peak effect is dangerous.supported
No significant interaction between midazolam-fentanyl and alcohol at 4h post-injection. pmid:1751272
Claim in safety — inconclusiveinconclusiveworking →
Macrolide antibiotics (erythromycin, clarithromycin), HIV protease inhibitors (ritonavir), calcium channel blockers (diltiazem, verapamil), nefazodone, and grapefruit juice also inhibit CYP3A4 sufficiently to cause clinically significant increases in midazolam exposure.supported
CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice) can cause excessive sedation with midazolam. pmid:10668858
Rifampin reduces oral midazolam AUC to approximately 24% of control values and IV AUC to approximately 59%supported
Rifampin (5-75 mg/d) decreased oral midazolam AUC to 24% of control and IV midazolam to 59% of control. clpt.2011.59
Tricyclic antidepressant co-ingestion creates a specific reversal hazard: midazolam protects against TCA-induced seizures, so administering flumazenil to reverse benzodiazepine effects in a patient who has also ingested a TCA unmasks the TCA's seizure and arrhythmia potential, with potentially fatal consequences.supported
Midazolam sedation protects against TCA seizures. Flumazenil reversal of midazolam in TCA overdose caused convulsions and arrhythmias. Contraindication warning for flumazenil in mixed TCA/BZD overdose. pmid:1586424
Failure to adjust doses when initiating potent CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, protease inhibitors) has caused excessive sedation and respiratory depression.supported
CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice) can cause excessive sedation with midazolam. Doubling of plasma concentration has potential for enhanced adverse response. pmid:10668858
Severe hepatic impairment requires dose reduction due to decreased clearance (37% reduction in cirrhosis) and increased free fraction.supported
Clearance 637 ml/min normal vs 402 ml/min cirrhotic. Free fraction 1.9% controls vs 4.9% cirrhotic. pmid:3395535
Severe renal impairment requires dose reduction and enhanced monitoring due to accumulation of the pharmacologically active glucuronide metabolite.supported
Warning: active metabolites accumulate in renal failure. pmid:7603229
Reversal of benzodiazepine-mediated seizure protection unmasks TCA-induced seizures and cardiac arrhythmias, which may be fatal.supported
Midazolam sedation protects against TCA seizures. Flumazenil reversal of midazolam in TCA overdose caused convulsions and arrhythmias. pmid:1586424
Monitor for resedation for ≥2 hours after apparent recovery, as midazolam outlasts flumazenilsupported
Duration of action 30-60 minutes; supplemental doses may be needed. pmid:1724638
Do NOT administer flumazenil if TCA co-ingestion is possiblesupported
Contraindication warning for flumazenil in mixed TCA/BZD overdose. pmid:1586424
pharmacology20 · 16 ok
The compound binds to the benzodiazepine recognition site located at the interface between α and γ2 subunits (the α+/γ2− subunit interface), potentiating the effect of endogenous GABA without directly activating the receptor in GABA's absencesupported
Actions of benzodiazepines due to potentiation of GABA-mediated neural inhibition. All effects result from GABA-A receptor actions. 978-3-540-74806-9_16
Midazolam does not meaningfully discriminate between GABA-A receptor subtypes containing α1, α2, α3, or α5 subunits (each combined with β and γ2 subunits) and is classified as a non-selective benzodiazepine site agonistsupported
GABAAR isoforms dictate pharmacology of anesthetics. Overview of GABA-A subtype selectivity. s40263-024-01128-6
Because midazolam potentiates all four subunit combinations, it produces the complete benzodiazepine effect profile — sedation, amnesia, anxiolysis, muscle relaxation, and anticonvulsant activity — without the dissociation between these effects achievable with subtype-selective compounds.supported
GABAAR isoforms dictate pharmacology of anesthetics. Remimazolam is a modified midazolam using soft pharmacology. Overview of GABA-A subtype selectivity. s40263-024-01128-6
Midazolam is approximately 2–4 times as potent as diazepam on a milligram basis.supported
Midazolam approximately 2-4x as potent as diazepam. pmid:3319363
Oral bioavailability is approximately 41–50% in young adults, limited by extensive first-pass hepatic and intestinal CYP3A4 metabolism; this value increases to approximately 50% in elderly mensupported
Oral bioavailability: 41-50%. pmid:6742481
Buccal bioavailability ranges from 28% (brief exposure) to 66% (100-second buccal mucosal contact), reflecting saturable transmucosal absorptionsupported
Absolute bioavailability increased from 27.8% (drinking solution) to 66.1% after 100-sec buccal exposure with saturation. jcph.1751
Claim in pharmacology — inconclusiveinconclusiveworking →
Distribution is characterized by a volume of distribution (Vd) of 1.3–2.0 L/kg in young adults, increasing substantially in elderly men (~2.47 L/kg) and obese patients (311 L vs. 114 L in matched controls) due to partitioning into adipose tissuesupported
Vd: 1.3 L/kg. Obesity increases Vd significantly. pmid:6742481
Distribution is characterized by a volume of distribution (Vd) of 1.3–2.0 L/kg in young adults, increasing substantially in elderly men (~2.47 L/kg) and obese patients (311 L vs. 114 L in matched controls) due to partitioning into adipose tissuesupported
Vdss significantly increased in elderly: 2.47 vs 1.22 L/kg (males). pmid:3582373
Distribution is characterized by a volume of distribution (Vd) of 1.3–2.0 L/kg in young adults, increasing substantially in elderly men (~2.47 L/kg) and obese patients (311 L vs. 114 L in matched controls) due to partitioning into adipose tissuesupported
Vd: 1.3 L/kg. Obesity increases Vd significantly. pmid:6742481
Plasma protein binding is high (96–98%, primarily albumin), with free fraction increasing in hepatic cirrhosis (4.9% vs. 1.9% in controls).supported
Free fraction 1.9% controls vs 4.9% cirrhotic. pmid:3395535
Elimination half-life is approximately 2.1 hours in young males but extends to 5.6 hours in elderly males and 8.52 hours in males over 80 yearssupported
IV midazolam t1/2: 2.1h young males, 5.6h elderly males. pmid:6742481
Elimination half-life is approximately 2.1 hours in young males but extends to 5.6 hours in elderly males and 8.52 hours in males over 80 yearssupported
t1/2 prolonged in elderly males: 8.52h vs 2.77h. pmid:3582373
Total plasma clearance averages 637 ml/min in normal patients and falls to 402 ml/min in cirrhosissupported
Clearance 637 ml/min normal vs 402 ml/min cirrhotic. pmid:3395535
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
CYP3A5 contributes to interindividual variability, with minor CYP2C19 involvementsupported
Midazolam PGx mainly mediated by CYP3A4, CYP3A5, and UDP-glucuronosyltransferase variations. fpc.0000000000000582
The 1'-hydroxymidazolam-β-D-glucuronide retains pharmacological activity at the benzodiazepine receptor (Ki ~16 nmol/L vs. parent compound Ki ~1.4 nmol/L), and accumulates in renal failure to cause prolonged sedation reversible by flumazenil.supported
Affinity to benzodiazepine receptor only 10x weaker than midazolam. Warning: active metabolites accumulate in renal failure. Prolonged sedation reversed by flumazenil. pmid:7603229
The 1'-hydroxymidazolam-β-D-glucuronide retains pharmacological activity at the benzodiazepine receptor (Ki ~16 nmol/L vs. parent compound Ki ~1.4 nmol/L), and accumulates in renal failure to cause prolonged sedation reversible by flumazenil.supported
1'-OH-midazolam is pharmacologically active major metabolite. Accumulation due to hepatic/renal dysfunction may enhance pharmacological activity. fmc.2025.156700
summary10 · 9 ok
Approximately 2–4 times as potent as diazepam on a milligram basis, midazolam produces sedation, anxiolysis, and anterograde amnesia with a total duration of 2–6 hours depending on route of administration.supported
Midazolam approximately 2-4x as potent as diazepam. Water soluble, rapid onset, short duration, mild CV and respiratory effects. pmid:3319363
Synthesized in 1975 by Armin Walser and Rodney Fryer at Hoffmann-La Roche, midazolam was the first benzodiazepine designed for water solubility — the imidazole ring opens at acidic pH, permitting stable injectable formulations, then closes at physiological pH to become highly lipophilic for rapid CNS penetrationsupported
pH-dependent water solubility from protonation of primary amine. Lipophilic at physiological pH. j.1875-9114.1985.tb03411.x
Current investigational focus includes intranasal delivery for seizure clusters (Nayzilam, FDA 2019), pharmacogenomic predictors of response, and neural circuit mechanisms of consciousness alteration.supported
MDZ-NS approved by FDA 2019 for seizure clusters in patients ≥12 years. 14737175.2021.1890033
Current investigational focus includes intranasal delivery for seizure clusters (Nayzilam, FDA 2019), pharmacogenomic predictors of response, and neural circuit mechanisms of consciousness alteration.supported
GABRB1 polymorphisms rs73247636 and rs56278524 significantly associated with Ramsay sedation scores and anterograde amnesia after midazolam 0.05 mg/kg IV. s13041-024-01141-2
Current investigational focus includes intranasal delivery for seizure clusters (Nayzilam, FDA 2019), pharmacogenomic predictors of response, and neural circuit mechanisms of consciousness alteration.supported
Reveals role of LC-VLPO noradrenergic circuit in regulating midazolam-induced altered consciousness. elife.97954
Midazolam binds the benzodiazepine recognition site at the α+/γ2− subunit interface of GABA-A receptors, potentiating GABA-mediated chloride conductance without direct receptor activationsupported
Actions of benzodiazepines due to potentiation of GABA-mediated neural inhibition. All effects result from GABA-A receptor actions. 978-3-540-74806-9_16
Claim in summary — inconclusiveinconclusiveworking →
Physical and psychological dependence develop with regular use; tolerance to sedative, anxiolytic, and anticonvulsant effects occurs through GABA-A receptor α1 subunit downregulation and receptor uncouplingsupported
Chronic benzodiazepine exposure produces tolerance via uncoupling of GABA and BZD sites and transcriptional downregulation of GABA-A receptor alpha1 subunit through L-type voltage-gated calcium channel activation. j.neulet.2020.134801
Physical and psychological dependence develop with regular use; tolerance to sedative, anxiolytic, and anticonvulsant effects occurs through GABA-A receptor α1 subunit downregulation and receptor uncouplingsupported
Chronic BZD causes tolerance associated with GABA-A receptor downregulation. Discontinuation causes receptor upregulation and withdrawal syndrome. Changes in gene expression for GABA-A receptor subunits occur. pmid:1652596
The active glucuronide metabolite (1'-hydroxymidazolam-β-D-glucuronide) accumulates in renal failure, causing prolonged sedation — a safety concern incompletely characterized in clinical practice guidelines.supported
Conjugated alpha-hydroxymidazolam accumulated. Affinity to benzodiazepine receptor only 10x weaker than midazolam. Warning: active metabolites accumulate in renal failure. pmid:7603229
clinical-evidence9 · 5 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →
The Nayzilam (midazolam nasal spray, 5 mg) Phase III pivotal trial demonstrated efficacy in seizure cluster termination in patients aged ≥12 years, supporting FDA approval in 2019supported
MDZ-NS approved by FDA 2019 for seizure clusters in patients ≥12 years. Safety and efficacy from Phase I and III trials reviewed. 14737175.2021.1890033
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Midazolam has Level A evidence for the treatment of convulsive status epilepticus via intramuscular administrationsupported
IM midazolam, IV lorazepam, IV diazepam and IV phenobarbital established as efficacious for SE (Level A). 1535-7597-16.1.48
A randomized controlled trial comparing intranasal, buccal, and intramuscular routes in pediatric patients confirmed comparable efficacy across non-IV delivery methods.supported
RCT comparing IN vs buccal vs IM midazolam for acute seizures in children at home and ER. j.pediatrneurol.2024.06.014
Claim in clinical-evidence — inconclusiveinconclusiveworking →
In a pediatric cardiac ICU cohort, dose-dependent tolerance was observed with escalating infusion requirements.supported
Midazolam has dose-dependent potential to induce tolerance, withdrawal, and hemodynamic depression in pediatric ICU. 0218492315585644
Observational cohort data confirm widespread midazolam use for refractory symptoms in cancer patients at end of life.supported
Evaluation of midazolam use role and trends in cancer patients dying in university hospital oncology ward. Midazolam used for refractory symptoms near death. s1478951525100461
pharmacokinetic-detail9 · 5 ok
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Age modestly increases oral bioavailability (to ~50% in elderly men), likely through reduced first-pass extractionsupported
Oral bioavailability: 41-50%. pmid:6742481
Buccal bioavailability is exposure-time dependent: 28% with immediate swallowing versus 66% with 100-second buccal mucosal contact, reflecting saturable absorption kinetics.supported
Absolute bioavailability increased from 27.8% (drinking solution) to 66.1% after 100-sec buccal exposure with saturation. jcph.1751
The markedly increased Vd in elderly and obese patients reflects partitioning into adipose tissue, prolonging the terminal elimination phase and extending clinical durationsupported
Vd: 1.3 L/kg. Obesity increases Vd significantly. pmid:6742481
Age effects on half-life are sex-dependent: elderly males show a 2.7-fold prolongation compared with young males, while women show no statistically significant age effectsupported
IV midazolam t1/2: 2.1h young males, 5.6h elderly males. pmid:6742481
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
The resulting 1'-hydroxymidazolam-β-D-glucuronide retains activity at the benzodiazepine receptor (Ki ~16 nmol/L) and is renally eliminatedsupported
Conjugated alpha-hydroxymidazolam accumulated. Affinity to benzodiazepine receptor only 10x weaker than midazolam. pmid:7603229
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
neuroscience7 · 4 ok
Allosteric modulation and the tolerance problem: The molecular mechanisms of benzodiazepine tolerance — α1 subunit transcriptional downregulation via L-type voltage-gated calcium channel activation, and GABA-A receptor phosphorylation-mediated uncoupling — frame tolerance not as a simple receptor desensitization but as a gene-expression-level adaptation that takes days to develop and weeks to reverse, explaining both the gradual onset of tolerance and the prolonged withdrawal syndrome.supported
Chronic benzodiazepine exposure produces tolerance via uncoupling of GABA and BZD sites and transcriptional downregulation of GABA-A receptor alpha1 subunit through L-type voltage-gated calcium channel activation. j.neulet.2020.134801
Allosteric modulation and the tolerance problem: The molecular mechanisms of benzodiazepine tolerance — α1 subunit transcriptional downregulation via L-type voltage-gated calcium channel activation, and GABA-A receptor phosphorylation-mediated uncoupling — frame tolerance not as a simple receptor desensitization but as a gene-expression-level adaptation that takes days to develop and weeks to reverse, explaining both the gradual onset of tolerance and the prolonged withdrawal syndrome.supported
Chronic BZD causes tolerance associated with GABA-A receptor downregulation. Changes in gene expression for GABA-A receptor subunits occur. Discontinuation causes receptor upregulation and withdrawal syndrome. pmid:1652596
Recovery of consciousness following midazolam sedation involves α1-adrenergic receptor activation in this circuit, suggesting that midazolam-induced unconsciousness is mechanistically related to the natural sleep-promoting pathway rather than representing a non-specific depression of cortical activity.supported
Reveals role of LC-VLPO noradrenergic circuit in regulating midazolam-induced altered consciousness. Effect mediated by alpha-1 adrenergic receptors. elife.97954
Claim in neuroscience — inconclusiveinconclusiveworking →
This has implications for understanding the quality of sedation — midazolam produces a sleep-like state that can be reversed by noradrenergic reactivation, unlike the cortical-subcortical disconnection produced by NMDA antagonists or volatile anesthetics.supported
Reveals role of LC-VLPO noradrenergic circuit in regulating midazolam-induced altered consciousness. Effect mediated by alpha-1 adrenergic receptors. elife.97954
Claim in neuroscience — not_supportednot supportedworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
comparative-pharmacology4 · 4 ok
Midazolam is 2–4 times more potent than diazepam on a milligram basissupported
Midazolam approximately 2-4x as potent as diazepam. pmid:3319363
For status epilepticus, IM midazolam has supplanted IV diazepam in prehospital protocols because IM delivery does not require venous access and achieves comparable seizure termination rates.supported
IM midazolam superior vs IV lorazepam without IV access (Level A). IM midazolam, IV lorazepam, IV diazepam and IV phenobarbital established as efficacious for SE. 1535-7597-16.1.48
Lorazepam's lack of active metabolites is theoretically advantageous in renal impairment, where midazolam's active glucuronide accumulates.supported
Warning: active metabolites accumulate in renal failure. pmid:7603229
This confers organ-independent metabolism, predictable offset regardless of infusion duration, and minimal drug interaction liability — directly addressing midazolam's limitations in prolonged ICU use and in patients with hepatic or renal impairment.supported
Remimazolam has classical benzodiazepine pharmacological profile like midazolam but differentiated by rapid conversion to inactive metabolite. fphar.2021.690875
history4 · 3 ok
In 2019, the FDA approved Nayzilam (midazolam nasal spray, 5 mg per spray) for the acute treatment of seizure clusters (intermittent, stereotypic episodes) in patients aged ≥12 years with epilepsysupported
MDZ-NS approved by FDA 2019 for seizure clusters in patients ≥12 years. 14737175.2021.1890033
In 2019, the FDA approved Nayzilam (midazolam nasal spray, 5 mg per spray) for the acute treatment of seizure clusters (intermittent, stereotypic episodes) in patients aged ≥12 years with epilepsysupported
Three FDA-approved rescue therapies: diazepam rectal gel (1997), midazolam nasal spray (2019 ≥12y), diazepam nasal spray (2020 ≥6y). s40263-023-01060-1
The association between benzodiazepines and GABAergic mechanisms was established approximately fifteen years after the class's initial discovery.supported
In 1955, Hoffmann-La Roche chemist Leo Sternbach serendipitously identified the first benzodiazepine, chlordiazepoxide. It took 15 years for researchers to associate benzodiazepines with GABA mechanism. tcp.n.2013.538
Claim in history — inconclusiveinconclusiveworking →
receptor-pharmacology4 · 3 ok
Genetic variants rs73247636 and rs56278524 in the GABA-A receptor β1 subunit gene (GABRB1) are significantly associated with interindividual variation in both sedative depth (Ramsay sedation score) and anterograde amnesia following standardized midazolam 0.05 mg/kg IVsupported
GABRB1 polymorphisms rs73247636 and rs56278524 significantly associated with Ramsay sedation scores and anterograde amnesia after midazolam 0.05 mg/kg IV. N=191 patients. s13041-024-01141-2
Midazolam is non-selective across these four subtypessupported
GABAAR isoforms dictate pharmacology of anesthetics. Overview of GABA-A subtype selectivity. s40263-024-01128-6
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
This is clinically significant because the glucuronide, which is normally renally cleared, accumulates in patients with renal impairment and causes prolonged sedation that responds to flumazenil.supported
Five patients with severe renal failure had prolonged sedation reversed by flumazenil. Conjugated alpha-hydroxymidazolam accumulated. pmid:7603229
chemistry2 · 2 ok
Midazolam belongs to the imidazobenzodiazepine subclass — the first and prototypical member of this structural familysupported
Midazolam is an imidazobenzodiazepine with unique properties compared with other benzodiazepines. pmid:3156545
This structural modification confers a pH-dependent conformational switch that is pharmaceutically critical: at pH < 4, protonation of the imidazole nitrogen opens the diazepine ring, rendering the compound freely water-soluble in acidic injectable formulations (buffered to pH 2.9–3.7); at physiological pH (> 4), the ring closes and midazolam becomes highly lipophilic, enabling rapid blood-brain barrier penetration.supported
Water soluble in acid formulation but highly lipid soluble in vivo. pmid:3156545